STEM Animal Health Inc. 지분 매각
DESJARDINS RI USA 저탄소 지수 ETF 단위
$38.03
11:15 14/05/24
애니멀케어 그룹 plc
("애니멀케어", "회사" 또는 "그룹")
Sale of equity in STEM Animal Health Inc. to Dechra Pharmaceuticals Limited
Exclusive Licence and Distribution Agreement for biofilm products enhanced
11 4월 2024. Animalcare Group plc (AIM: ANCR), the international animal health business, today announces that it has reached agreement in principle to sell its 33.34% equity stake in STEM Animal Health Inc. (STEM) to Dechra Pharmaceuticals Limited ("Dechra") for a total cash payment of US$4.7m, payable upon completion of the transaction. STEM is currently owned by Animalcare and Canada-based Kane Biotech Inc. ("Kane Biotech").
Other items covered by the agreement (the "Agreement") will bring the total potential monetary value of the deal for the Group to approximately US$5.4m. The sale of the minority stake secures a positive return on investment for Animalcare while further strengthening the Group's cash position following the disposal of Identicare announced on 28 February 2024.
STEM was established in September 2020 as a joint venture by Animalcare and Kane Biotech with a focus on treating biofilm-related ailments in animals. Under that agreement, Animalcare was granted rights to commercialise products based on Kane Biotech's coactiv+TM and DispersinB® technology in global veterinary markets outside the Americas.
Under the terms of the Agreement, the existing licence and distribution agreement with STEM will be extended to allow Animalcare access to all channels in Europe and the UK. This means Animalcare can maximise the value of the dental franchise through both veterinary and retail channels including via e-commerce.
In addition, Animalcare will maintain influence over the choice of new product development options associated with the licensed intellectual property through a newly formed joint innovation team with Dechra and Kane Biotech.
Completion of the transaction requires the consent of more than 50% of the shareholders of Kane Biotech.
Chief Executive Officer of Animalcare, Jenny Winter said: "This transaction offers value for Animalcare on several levels. Not only have we secured an attractive return on our equity investment in STEM that adds to our investment firepower, we have gained enhanced commercial licensing rights that grant us more options to reach pet owners in these key markets. Further into the future, I'm also excited about the potential to accelerate development of new biofilm-targeting products by combining the knowledge and resources of all three parties."
동물보호에 대해
Animalcare Group plc는 영국 AIM에 등재된 국제 수의 판매 및 마케팅 조직입니다. Animalcare는 40개국에서 운영되고 있으며 유럽 및 전 세계의 약 XNUMX개국에 수출하고 있습니다. 그룹은 자체 개발 파이프라인, 파트너십 및 인수를 통해 새롭고 혁신적인 제품을 시장에 출시하는 데 중점을 두고 있습니다.
동물보호에 대한 자세한 내용은 다음을 방문하십시오. www.animalcaregroup.com 또는 문의 :
애니멀케어 그룹 plc 제니 윈터, 최고 경영자 크리스 브루스터(Chris Brewster), 최고재무책임자(CFO) 미디어/투자자 관계
| +44 (0)1904 487 687
|
스티펠 니콜라우스 유럽 제한 벤 매디슨 닉 아담스 닉 할랜드 프랜시스 노스
| +44 (0)20 7710 7600 |
판 뮤어 고든 (관절 Broker) 기업 금융 프레디 크로슬리/엠마 얼 기업 중개 루퍼트 디어든
| +44 (0)20 7886 2500 |
RNS는 귀하의 IP 주소를 사용하여 약관 준수 여부를 확인하고, 귀하가 이 커뮤니케이션에 포함된 정보를 사용하는 방식을 분석하고, 그러한 분석을 익명으로 다른 사람과 상용 서비스의 일부로 공유할 수 있습니다. RNS와 런던 증권 거래소가 귀하가 제공한 개인 데이터를 사용하는 방법에 대한 자세한 내용은 개인 정보 보호 정책을 참조하십시오.